N'1-(3-chlorobenzoyl)-3-nitrobenzene-1-carbohydrazide | 316149-08-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N'1-(3-chlorobenzoyl)-3-nitrobenzene-1-carbohydrazide
• 英文别名: 3′-chloro-N'-(3-nitrobenzoyl)benzohydrazide；3-chloro-N'-[(3-nitrophenyl)carbonyl]benzohydrazide；N'-(3-chlorobenzoyl)-3-nitrobenzohydrazide
• CAS: 316149-08-3
• 化学式: C₁₄H₁₀ClN₃O₄
• 分子量: 319.704
• InChiKey: HMKORZHONFIOSC-UHFFFAOYSA-N

物化性质

• 沸点：
  601.7±55.0 °C(Predicted)
• 密度：
  1.441±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  104
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N'1-(3-chlorobenzoyl)-3-nitrobenzene-1-carbohydrazide 在 氯化铵 、 锌 、 三氯氧磷 作用下， 以 四氢呋喃 、 甲醇 、 水 、 乙腈 为溶剂， 反应 12.0h， 生成 3-amino-[2-(3-chlorophenyl)-1,3,4-oxadiazol-5-yl]benzene
  参考文献：
  名称：

  Design, Synthesis and Biological Activity Evaluation of 2,5-Diphenyl-1,3,4-oxadiazole Derivatives as Novel Inhibitors of Fructose-1,6-bisphosphatase

  摘要：

  Fructose-1,6-bisphosphatase (FBPase), an important gluconeogenic enzyme, catalyzes the hydrolysis of fructose 1,6-bisphosphate to fructose 6-phosphate. The effort to discover new FBPase inhibitors was carried out by high-throughput screening (HTS) of a library of 56,000 lead-like compounds, and a 2,5-diphenyl-1,3,4-oxadiazole (3a, IC50 = 15.45 mu M) which bearing no phosphate group was identified as a potential FBPase inhibitor for the first time. Structure-activity-relationship (SAR) research of a series of analogues obtained by modifying the substituent groups and replacing the 1,3,4-oxadiazole with several other heterocycles disclosed the key structure and substituent groups related to the binding with FBPase.

  DOI：

  10.3987/com-12-12565
• 作为产物：
  描述：

  3-硝基苯甲酸甲酯 在 3-甲基吡啶 、 1-羟基苯并三唑 、 一水合肼 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 18.0h， 生成 N'1-(3-chlorobenzoyl)-3-nitrobenzene-1-carbohydrazide
  参考文献：
  名称：

  Design, Synthesis and Biological Activity Evaluation of 2,5-Diphenyl-1,3,4-oxadiazole Derivatives as Novel Inhibitors of Fructose-1,6-bisphosphatase

  摘要：

  Fructose-1,6-bisphosphatase (FBPase), an important gluconeogenic enzyme, catalyzes the hydrolysis of fructose 1,6-bisphosphate to fructose 6-phosphate. The effort to discover new FBPase inhibitors was carried out by high-throughput screening (HTS) of a library of 56,000 lead-like compounds, and a 2,5-diphenyl-1,3,4-oxadiazole (3a, IC50 = 15.45 mu M) which bearing no phosphate group was identified as a potential FBPase inhibitor for the first time. Structure-activity-relationship (SAR) research of a series of analogues obtained by modifying the substituent groups and replacing the 1,3,4-oxadiazole with several other heterocycles disclosed the key structure and substituent groups related to the binding with FBPase.

  DOI：

  10.3987/com-12-12565

文献信息

• 2,4-Pyrimidinediamine Compounds and Their Uses
  申请人：Singh Rajinder

  公开号：US20150266828A1

  公开（公告）日：2015-09-24

  The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

  本发明提供了抑制IgE和/或IgG受体信号级联反应的2,4-嘧啶二胺化合物，该级联反应导致化学介质的释放，以及合成这些化合物的中介体和方法，以及在多种情况下使用这些化合物的方法，包括在治疗和预防由脱粒和其他由IgE和/或IgG受体信号级联反应激活引起的化学介质释放所表征、引起或相关的疾病。
• Synthesis and in vitro urease inhibitory activity of benzohydrazide derivatives, in silico and kinetic studies
  作者：Azhar Abbas、Basharat Ali、Kanwal、Khalid Mohammed Khan、Jamshed Iqbal、Shafiq ur Rahman、Sumera Zaib、Shahnaz Perveen

  DOI：10.1016/j.bioorg.2018.09.036

  日期：2019.2

  Benzohydrazide derivatives 1–43 were synthesized via “one-pot” reaction and structural characterization of these synthetic derivatives was carried out by different spectroscopic techniques such as 1H NMR and EI-MS. The synthetic molecules were evaluated for their in vitro urease inhibitory activity. All synthetic derivatives showed good inhibitory activities in the range of (IC50 = 0.87 ± 0.31–19.0 ± 0

  苯甲酰肼衍生物1 - 43合成通过“一锅”反应和这些合成衍生物的结构表征通过不同光谱技术如进行1 H NMR和EI-MS。评价合成分子的体外脲酶抑制活性。所有合成的衍生物表现出的范围内具有良好的抑制活性（IC 50  = 0.87±0.31-19.0±0.25μM）相比于标准的硫脲（IC 50  = 21.25±0.15μM），除了7和化合物17，18，23，24，29，30，以及发现41个处于非活动状态的。该系列中活性最高的化合物是化合物36（IC 50  = 0.87±0.31μM），在A环的间位有两个氯基，B环的对位有两个甲氧基。化合物是基于不同的取代基及其在分子中的位置建立的。活性化合物的动力学研究表明，化合物可以通过竞争和非竞争模式抑制酶。还进行了计算机分析，以了解分子（配体）与酶活性位点的结合相互作用。
• 2, 4-pyrimidinediamine compounds and their uses
  申请人：Singh Rajinder

  公开号：US20050038243A1

  公开（公告）日：2005-02-17

  The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

  本发明提供了抑制IgE和/或IgG受体信号级联，从而导致化学介质释放的2,4-嘧啶二胺化合物，以及合成这些化合物的中间体和方法，以及在多种情况下使用这些化合物的方法，包括在治疗和预防通过去颗粒化和其他由IgE和/或IgG受体信号级联激活的过程引起或与之相关的化学介质释放所表征的疾病中使用。
• 2,4-Pyrimidinediamine compounds and their uses
  申请人：——

  公开号：US20040029902A1

  公开（公告）日：2004-02-12

  The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

  本发明提供了抑制IgE和/或IgG受体信号级联引起化学介质释放的2,4-嘧啶二胺化合物，以及合成这些化合物的中间体和方法，以及在多种情境下使用这些化合物的方法，包括在治疗和预防由通过激活IgE和/或IgG受体信号级联引起的脱颗粒化和其他过程释放化学介质的疾病中。
• 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES
  申请人：Singh Rajinder

  公开号：US20070225321A1

  公开（公告）日：2007-09-27

  The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

  本发明提供了能够抑制IgE和/或IgG受体信号级联反应从而导致化学介质释放的2,4-嘧啶二胺化合物，以及合成这些化合物的中间体和方法，以及在各种情况下使用这些化合物的方法，包括用于治疗和预防通过去颗粒化和其他通过激活IgE和/或IgG受体信号级联反应引起的化学介质释放所表征的，由化学介质引起或相关的疾病。